- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic hepatitis D
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 679KB)
Bulevirtide – March 2024
Bulevirtide: Powder for injection 2 mg; Hepcludex®
Last updated
30 May 2025